Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia

Secondary acute myeloid leukemia (sAML) is a high-risk AML evolving from heterogenous prior hematological disorders. Compared to de novo AML, sAML has even worse responses to current therapy and thus is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hui, Gan, Wen-Ting, Hao, Wen-Ge, Wang, Peng-Fei, Li, Zhuo-Yan, Chang, Lung-Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266936/
https://www.ncbi.nlm.nih.gov/pubmed/32528876
http://dx.doi.org/10.3389/fonc.2020.00685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7266936/
https://www.ncbi.nlm.nih.gov/pubmed/32528876
http://dx.doi.org/10.3389/fonc.2020.00685

Ejemplares similares